Cerebrum Compositum N 2.2 ml N5 injection solution

Composition of the drug Cerebrum compositum

2.2 ml of drug solution contains:

• Cerebrum suis D8;
• Hepar suis D10;
• Embryosuis D10;
• Kalium phosphoricum D6;
• Placenta suis D10;
• Thuja occidentalis D6;
• SeleniumD10;
• Bothrops lanceolatus D10;
• Ignatia D8;
• China D4;
• Acidumphosphoricum D10;
• Magnesium phosphoricum D10;
• Manganum phosphoricum D8;
• Conium maculatum D4;
• Semecarpus anacardium D6;
• Hyoscyamus niger D6;
• Medorrhinum-Nosode D13;
• Anamirta cocculus D4;
• Aconitum napellus D6;
• Sulfur D10;
• Ambra grisea D10;
• Gelsemium sempervirens D4;
• Kalium bichromicum D8;
• Arnica montana D28;
• Ruta graveolens D4;
• Aesculus hippocastanum D4.

conclusions

The results of the reviewed clinical studies confirm that the use of CBP Cerebrum compositum N can significantly expand the possibilities of pharmacotherapy for children with neurological pathology. Its therapeutic effectiveness and favorable safety profile have been confirmed, the ability to be used either independently or included in treatment regimens, combined with traditional drugs, which gives the pediatric neurologist wider and more flexible opportunities when designing and conducting complex therapy.

Indications for use of Cerebrum compositum

According to the instructions for Cerebrum compositum, this drug is indicated for:

• encephalopathies of various origins;
• vegetative-vascular dystonia;
• depression;
• treatment of consequences of traumatic brain injuries;
• post-stroke conditions;
• encephalitis;
• complications after neurosurgical interventions;
• neuralgia;
• neurasthenia;
• multiple sclerosis;
• decreased attention;
• atrophic lateral sclerosis;
• memory disorders;
• Parkinson's disease;
• geriatric changes in the central nervous system;
• cerebral palsy;
• developmental delay (mental, physical) in children;
• to stimulate regenerative processes and nonspecific immunity;
• for diseases of the veins, arteries, local pathology of venous circulation;
• for the prevention of atherosclerotic blood supply disorders;
• to prevent mental decline due to chronic stress;
• for migraines, organic lesions of the central nervous system.

The attitude of the broad mass of doctors towards homeopathy is ambiguous: from benevolently interested to irritably skeptical. The latter especially applies to psychiatrists, who look at homeopathic therapy with a certain wariness, believing that ultra-low doses are unacceptable in psychiatry, and the principle of similarity is applicable only to intoxication psychoses. However, every year interest increasingly prevails over skepticism, since a huge arsenal of psychopharmacological agents is not always able to cope with mental disorders, and often psychopharmacotherapy itself becomes the cause of new types of pathology. In psychiatry, there are increasingly calls to compare the benefits and harms caused by psychopharmacological treatment, and to be guided by this principle in the treatment of each individual patient.

In their practice, homeopathy (usually in its modern form, which consists in prescribing complex drugs according to the stated indications for use, and not in the form of classical monogomoeopathy) is used by 25% of doctors in Germany, 45% of doctors in England, 32% in France.

In the USA in the 1980s. Sales of homeopathic medicines increased by 500%. In 1995, the Ministry of Health of the Russian Federation also legalized the use of homeopathic methods in medical practice.

However, the use of classical homeopathy for the treatment of mental illness does present some difficulties due to the need for the patient’s active participation in treatment, adherence to a certain therapeutic discipline when using several single homeopathic remedies, which is not always possible in cases of mental pathology. In addition, the long duration of treatment and the delayed onset of effect also did not contribute to the spread of homeopathy in psychiatry.

The situation changed after Dr. H.-H. Reckeweg in Germany in the 1960s. The doctrine of homotoxicology was developed, which essentially combined homeopathy and allopathy. The idea that diseases arise as biologically expedient protective actions of the body directed against endogenous and exogenous homotoxins does not contradict existing theories of the occurrence of mental disorders. Moreover, for a long time there was even a theory of the toxic origin of schizophrenia, and epidemiological studies of recent decades have stated the possibility of an increase in the number of cases of schizophrenia under the influence of changed environmental conditions.

In turn, borderline neuropsychiatric disorders are, as it were, nonspecific precursors of the initial phase of various pathological processes (including exogenous toxic ones) and can be associated with autoimmune processes, the formation of endogenous toxins and retoxins.

Proposed by H.-H. Reckeweg's 6-phase pathway of interaction between homotoxins and the body can also be applied to the clinical and pathogenetic mechanisms of mental disorders. Thus, neurotic conditions, as well as acute intoxication disorders, can be attributed to the humoral stages of the pathological process, while chronic forms of schizophrenia, debilitating processes and neuroleptic syndromes are the cellular phases of the disease. Here it is appropriate to recall that the idea of ​​a single psychosis, in which individual nosological forms are only stages of the development of a single disease process, has been expressed more than once. One of the greatest neurochemists of our time, Professor N.M. van Praag, believes that individual psychiatric nosologies can be different forms of reactions.

The great merit of H.-H. Reckeweg not only created the theory of homotoxicology, but also developed a number of complex drugs called antihomotoxic. They take into account the possibilities of potentiation, synergism and counteraction of individual components. But the most important thing is that complex preparations can be prescribed not only for homeopathic symptoms, but also depending on the allopathic diagnosis and the phase in which the process is located. A priori, it can be assumed that antihomotoxic drugs can be used in psychiatry for detoxification, stimulation of the body's defenses, and restoration of impaired regulatory processes.

The most studied of the antihomotoxic drugs, the use of which is effective for mental disorders, is Cerebrum compositum N. The drug contains 26 components of plant, mineral and animal origin. More than 10 works published only in Russian in recent years have been devoted to the study of the action of Cerebrum compositum N. According to a multicentric study by M. Weiser and S. Zenner [4], based on the treatment of 731 patients with various, incl. mental illnesses, the drug is indicated for various disorders of brain function, and its action is aimed at preventing atherosclerotic circulatory disorders that cause weakening of brain activity. The authors identified clinical groups of patients with nervous exhaustion, memory loss, atherosclerosis, depression, and conditions after a concussion. The greatest effectiveness of the drug Cerebrum compositum N was noted in conditions after a concussion - 98% of the results were rated as good or excellent, with nervous exhaustion - 95%, with depression - 91%, with weakened memory - 90%, with states of excitement - more 90%, with vegetative dystonia - more than 95% of good and excellent grades.

Subsequent studies of the therapeutic activity of the drug Cerebrum compositum N deepened knowledge about its action and expanded the indications for its use.

In the study by S.E. Fursova [5] noted that the most clinically pronounced effect of Cerebrum compositum N in patients with asthenic disorders of various origins was anti-asthenic and psychostimulating effects, manifested in a decrease in feelings of weakness, fatigue, daytime sleepiness, the appearance of physical vigor, increased initiative and performance. Along with this, a decrease in anxiety, irritability, affective instability, and hyperesthesia was noted. Analysis of clinical, psychological, encephalo- and rheographic data allowed the authors [6] to suggest that the target for the drug Cerebrum compositum N is primarily anxiety, the reduction of which determines the further reduction of all other neurotic symptoms, incl. vegetative disorders. However, the authors do not deny the direct anti-asthenic effect of the drug, which is confirmed not only by the subjective change in the condition of patients, but also by changes in psychological testing indicators in critical sections of the performance curve for asthenic syndrome - in the phases of workability and fatigue.

The antiasthenic, redynamizing effects of the drug Cerebrum compositum N were also noted in the works of G.A. Zubovsky [7, 8], V.V. Nikolaev [18], who drew attention to the positive effect of the drug on mnestic functions, attention and the ability to concentrate. The effect of Cerebrum compositum N on short-term memory is especially pronounced, in which, in particular, the function of retaining traces significantly improves.

An electroencephalographic study of Cerebrum compositum N revealed a statistically significant decrease in spectral density in the narrow-band spectrum of the EEG electroencephalogram. Moreover, a comparison of the EEG profile of Cerebrum compositum N and some nootropics and tranquilizers made it possible to classify the drug as a mild antipsychotic with an anticholinergic component and antidepressant properties. G.A. Zubovsky, N.B. Kholodova et al. [8] claim that under the influence of treatment with this drug in patients with vascular pathology of the brain, not only positive clinical dynamics are observed, but also cortical irritation decreases and the severity of paroxysmal forms of activity decreases, and cortical rhythms are normalized.

The drug has a mild modulating effect on monoamine metabolism without causing depletion of neurotransmitter systems. The drug has an asymmetrical effect on the cerebral hemispheres: on the right - light sydnocarb-like, on the left - obsidan-like. The effectiveness of the drug Cerebrum compositum N is also confirmed by rheoencephalography data. During the treatment process, pulse blood filling and the intensity of venous outflow change, as evidenced by the diastolic index.

A detailed clinical study of the drug revealed that in some cases it has an exciting effect, the mood of patients becomes hyperthymic, and when performing psychological tests the number of errors increases and concentration of attention decreases. It is possible that these effects are associated with the anticholinergic effect of the drug, which may be excessive if there is increased individual sensitivity to it. In addition, the anticholinergic effect is dose-dependent and changing the frequency of drug administration quickly relieves side effects.

The presence of an anticholinergic component in the action of Cerebrum compositum N explains its effectiveness in another very important area of ​​psychiatry - the treatment of neuroleptic complications [9]. Neurolepsy as a complication of psychopharmacotherapy occurs, according to various authors, in more than 50% of patients. At the same time, the most common correctors - anticholinergics (cyclodol, parkopan, etc.) themselves create side effects, incl. and pathological dependence.

The authors observed 18 patients with schizophrenia aged from 19 to 47 years with a disease duration of one to 26 years, who received hospital treatment with various antipsychotics. Side effects manifested themselves in the form of tremor, hypertonicity, akathisia, hyperkenetic and dyskinetic disorders, tachycardia, hypersalivation and other somatovegetative disorders. All patients were prescribed Cerebrum compositum N as intramuscular injections every other day. After 9 days, the patients' condition was assessed on a 3-point scale. The symptoms of akathisia and tasykinesia, tremor, coordination disorders and hyperkinesis significantly decreased. These clinical findings appear to merit further study, as neurolepsy often makes achieving therapeutic efficacy difficult.

One of the important areas of use of antihomotoxic drugs is the treatment of Alzheimer's disease [10, 11]. The authors assume that biological therapy, through detoxification and metabolic activation, can cause symptomatic improvement. A description of a case of treatment of a patient with Alzheimer's disease shows that in the 4th–5th week of treatment with the drug Cerebrum compositum N, her health improved, the patient began to cope with practical tasks, and her ability to count and abstract logical thinking improved. Küstermann [10] included the catalyst Ubiquinone compositum in the treatment plan, as well as preparations with Ginkgo Biloba extract. And in the treatment regimens given by Ivo Bianchi [12], Cerebrum compositum N is named as the main stimulating and regenerative drug indicated for various mental disorders of late age.

Complex homeopathic medicines can be used as an auxiliary therapy in the treatment of epilepsy [17] to normalize the psycho-emotional and somatic status. Special attention should be paid to the use of biological drugs in child psychiatry. In the work of E.I. Ivanova et al. [16] provide data on the effective treatment of mental retardation with behavioral disorders using therapy with the drugs Cerebrum compositum N and Nervohel. The authors believe that biological drugs are highly effective therapies and can be used either alone or in combination with allopathic drugs.

Thus, the scope of effective use of complex homeopathic medicines in psychiatry is quite wide. At the same time, biological therapy can be used as the main therapy in the treatment of mental illnesses of intoxication, traumatic, atherosclerotic, and vascular origins.

The most curable syndromes are: asthenic, cerebrasthenic, anxiety, as well as intellectual-mnestic disorders. Biological therapy is effective as a primary or parallel therapy to relieve the toxic load - a side effect of psychopharmacotherapy - neurolepsy.

Complex homeopathic preparations are quite compatible with conventional psychopharmacotherapy and, possibly, increase sensitivity to psychopharmacological drugs. In addition, according to available data [20], the use of biological therapy can reduce healthcare costs with high efficiency and almost complete safety of such treatment methods, which should also increase interest in the use of complementary treatment methods (in this case, antihomotoxic drugs) in practical healthcare .

Directions for use, dosage

The drug Cerebrum compositum can be used subcutaneously, intradermally, intramuscularly, and sometimes intravenously. The average dosage is 1 ampoule. The frequency of administration is 1-3 times a week. For children aged 1-3 years, the drug is prescribed in a dosage of 1/6-1/4 ampoule volume, at the age of 3-6 years - in a dosage of 1/3-1/2 ampoule, after 6 years - 1 ampoule with a frequency of administration of 1- 2 times during the week.

The drug Cerebrum compositum can also be used orally. In this case, the contents of the ampoule should be dissolved in 50 ml of water and the resulting solution should be drunk during the day.

Possibilities of the bioregulatory approach

In the current situation, the search for medicines that would meet the following requirements remains relevant:

1) contributed to the improvement of motor and mental skills in sick children, accelerating the maturation of central nervous system structures, using other mechanisms of action;

2) made it possible to increase the effectiveness of treatment with a more favorable safety profile.

Recently, for the treatment of children with neurological pathology, along with traditional allopathic drugs, complex bioregulatory drugs (CBP) are increasingly used [7, 10]. At the pathogenetic level, they provide a comprehensive and balanced restoration of the regulatory, metabolic, energetic, protective and detoxification functions of the body. Previously, the term “antihomotoxic drugs” (AGD) was used in relation to PBC in the literature.

CBPs contain ultra-low doses of active substances of plant, mineral and animal origin, which help activate drainage and detoxification processes, improve metabolism and restore energy efficiency, which leads to the activation of self-healing processes of cells and tissues. An important property of CBP is the absence of pharmacokinetics. Ultra-small doses of active substances are not metabolized in the body and, therefore, do not require additional energy expenditure, and therefore do not have a pharmacological load on the body [1-3; 20]. The effect of these drugs is mainly aimed not at stimulating any specific organ, but at activating and developing the body’s hidden compensatory capabilities, the reserve of which in children, in most cases, is quite significant [10].